Pre-Exposure Prophylaxis PrEP
Pre-Exposure Prophylaxis PrEP Pre-Exposure Prophylaxis PrEP
Properties of an ideal PrEP agent• Potent• Safe• Easy to use• Long half-life• Good penetration into genital tract• High barrier to resistance• Different class of drug from ARVs for treatment• Affordable: drug and monitoring costsDerdelinckx et al PLOS Medicine 2006
Tenofovir (Viread) for PrEP• Nucleotide reverse transcriptase inhibitor (NRTI)• Made by Gilead Sciences• Blocks HIV replication by inhibiting reversetranscriptase enzyme• FDA-approved for HIV treatment in 2001, usedclinically in combination therapy in over 200,000patients• Favorable drug profile– Low incidence of side effects– Once daily dosing (300 mg)– No food requirement– Resistance slow to develop– Long intracellular half life– High concentration into genital tract
- Page 1 and 2: Narin Hiransuthikul MD, PhDDep. Pre
- Page 3 and 4: THAILANDAdult (15-49 years) HIV Pre
- Page 5 and 6: December 2009
- Page 7 and 8: ้วิธีการต่า
- Page 9 and 10: ่่้การใช้ยา
- Page 11 and 12: • The ongoing use of one or two a
- Page 14: Miller CJ, et al. J Virology 2005 :
- Page 17: WhyTenofovirand/orEmtricitabine?
- Page 21 and 22: เพร็พแบบกินOr
- Page 23 and 24: ีื่การศึกษา
- Page 25 and 26: ความสัมพันธ
- Page 27 and 28: ความท้าทายอ
- Page 29 and 30: PrEP would be an addition to, not a
- Page 31 and 32: HIVPost-Exposure Prophylaxis (PEP)
- Page 33: Last updated Jan 21, 2005© World H
- Page 36 and 37: ความเสี่ยงใ
- Page 38 and 39: Definitely Potentially Not infectio
- Page 40 and 41: Risk of HIV Occupational Transmissi
- Page 42 and 43: Estimated Pathogen‐Specific Seroc
- Page 44 and 45: Other Cofactors• Source HIV viral
- Page 46 and 47: 1. First aids2. Counseling & Assess
- Page 48 and 49: HIV PEP• Current multidrug regime
- Page 50 and 51: Indications for Occupational PEP*So
- Page 52 and 53: Recommended PEP RegimensBASIC REGIM
- Page 55 and 56: Preferred regimenARV regimens forHI
- Page 57 and 58: Follow-up of HCP exposed to known o
- Page 59 and 60: ููุตารางที่ 1
- Page 61 and 62: ตารางที่ 2.2 กา
- Page 63 and 64: Recommended PEP RegimensBASIC REGIM
- Page 65: ARV Regimens for HIV PEP• Raltegr
Tenofovir (Viread) for <strong>PrEP</strong>• Nucleotide reverse transcriptase inhibitor (NRTI)• Made by Gilead Sciences• Blocks HIV replication by inhibiting reversetranscriptase enzyme• FDA-approved for HIV treatment in 2001, usedclinically in combination therapy in over 200,000patients• Favorable drug profile– Low incidence of side effects– Once daily dosing (300 mg)– No food requirement– Resistance slow to develop– Long intracellular half life– High concentration into genital tract
Change language